Reflections on treatment of IBD in children and adolescents

Immunopharmacol Immunotoxicol. 2018 Dec;40(6):461-464. doi: 10.1080/08923973.2018.1474922. Epub 2018 Jul 24.

Abstract

Major pharmaceutical advancements in the field of inflammatory bowel diseases benefit to children and adolescents affected with this progressive chronic condition. Scientific organisations such as ESPGHAN and ECCO actively publish guidelines related to the many aspects of care from these patients. Clinical studies and long-term prospective registries in the appropriate age groups are crucial to support an evidence based strategy.

Keywords: Inflammatory bowel disease; children; clinical studies; pediatrics; treatment.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Age Factors
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use
  • Child
  • Clinical Studies as Topic
  • Humans
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use
  • Immunotherapy / methods
  • Immunotherapy / trends
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / epidemiology
  • Inflammatory Bowel Diseases / immunology
  • Practice Guidelines as Topic / standards*
  • Prospective Studies
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Immunologic Factors